Journal of Pain and Symptom Management
Volume 39, Issue 1 , Pages e8-e11 , January 2010

Pharmacogenetic Testing Is of Limited Utility for Predicting Analgesic Response to Morphine

References 

  1. World Health Organization. Cancer pain relief. 2nd ed. Geneva, Switzerland: World Health Organization; 1996;
  2. Cherny N, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76:1283–1293
  3. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today. 2001;6:835–839
  4. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008;83:559–566
  5. Bianchi M, Fornasari D, Antonini R, et al. The pharmacogenetics of morphine-induced analgesia: a case report. J Pain Symptom Manage. 2008;36:e10–e12
  6. Befort K, Filliol D, Decaillot FM, et al. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signalling. J Biol Chem. 2001;276:3130–3137
  7. Reyes-Gibby CC, Shete S, Rakvåg T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25–30
  8. Rana B, Shiina T, Insel P. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu Rev Pharmacol Toxicol. 2001;41:593–624
  9. Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005;15:693–704
  10. Ross JR, Riley J, Taegetmeyer A, et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer. 2008;112:1390–1403
  11. Zubieta J, Heitzeg M, Smith Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240–1243
  12. Nystedt J, Lemberg K, Lintunen M, et al. Pain- and morphine-associated transcriptional regulation of neuropeptide FF and the G-protein-coupled NPFF2 receptor gene. Neurobiol Dis. 2004;16:254–262
  13. Holthe M, Rakvåg TN, Klepstad P, et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 2003;3:17–26
  14. Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther. 2006;79:316–324
  15. García-Larrea L, Peyron R, Mertens P, et al. Functional imaging and neurophysiological assessment of spinal and brain therapeutic modulation in humans. Arch Med Res. 2000;31:248–257
  16. Janicki PK, Schuler G, Francis D, et al. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg. 2006;103:1011–1017
  17. Rakvåg TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005;116:73–78
  18. Lötsch J, Geisslinger G. Current evidence for a modulation of nociception by human genetic polymorphisms. Pain. 2007;132(1–2):18–22
  19. Chou WY, Wang CH, Liu PH, et al. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology. 2006;105(2):334–337
  20. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473–3478
  21. Hirota T, Ieiri I, Takane H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos. 2003;31:677–680
  22. Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther. 2004;75:223–233

PII: S0885-3924(09)00796-9

doi: 10.1016/j.jpainsymman.2009.08.004

Journal of Pain and Symptom Management
Volume 39, Issue 1 , Pages e8-e11 , January 2010

Article Tools